Celltrion

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • FX sensitivity: 8% move in USD/EUR/GBP/JPY/CHF impacts pre-tax profit by ±KRW 312.3B (2025) vs ±KRW 39.3B (2024) — EUR alone ±KRW 220.0B
• • Total borrowings surged to KRW 3,690B (2025) from KRW 2,162B (2024); net debt ratio doubled to 12.90% from 6.22%; debt ratio rose to 28.71% from 19.77%

Management Discussion & Analysis

• • Consolidated revenue KRW 4.16T (+17% YoY), operating profit KRW 1.17T (+137% YoY), net income KRW 1.03T (+146% YoY)
• • OP margin expanded to 28.1% (+14.2%p YoY); driven by full normalization of post-merger cost spike, improved product mix toward higher-margin new products, and SG&A leverage

Business Overview

• • Celltrion: global biosimilar leader; 11 approved biosimilar products + Zymfentra (CT-P13 SC) FDA novel drug approval; direct-sales model across EU, US, key markets
• • FY2025 revenue KRW 4,163B (+17% YoY), operating profit KRW 1,169B; biosimilars 93% of sales

What are the latest Celltrion DART filings in 2026?

Celltrion (KRX code 068270) has filed an annual report on March 16, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Celltrion file its most recent annual report?

Celltrion filed its most recent annual report on March 16, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Celltrion's KRX stock code?

Celltrion's KRX stock code is 068270. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 068270 to look up all Celltrion disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Celltrion file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Celltrion.

Where can I find Celltrion financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Celltrion annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.